Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » OTCBB Reporting Stocks » COBI » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is not enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
luckylindy  - posted
COBI NEWS:
Compass Biotechnologies Inc. invited to speak at The World Generic Medicines Congress Americas 2011:

Press Release Source: Compass Biotechnologies Inc. On Tuesday May 31, 2011, 10:45 am

http://finance.yahoo.com/news/Compass-Biotechnologies-Inc-prnews-3485536878.html ?x=0&.v=2

EDMONTON, May 31, 2011 /PRNewswire/ - Compass Biotechnologies (COBI:OB) is pleased to announce that Dr. Joseph Sinkule President and COO of Compass Biotech has been invited to speak at the fourth annual World Generic Medicines Congress Americas 2011 to be held this fall from November 12 - November 15 at the Westin Grand, Washington D.C.

The Congress is the largest of its kind within the Generics Industry and for the first time this year is expanding to include the World Biosimiliars Summit to help focus on the key challenges facing the commercialization of the soon to be multiple billion dollar biosimiliar US and global markets.

The meeting unites a speaker platform of the highest seniority with all stakeholders in the industry and allows participants to position their products and services in front of decision makers from major Pharma manufacturers and large biotech companies. Dr. Sinkule who will speak on "Strategies and Opportunities for Smaller and Niche Generic Companies"

Dr Sinkule commented "It is indeed an honour and a privilege to be invited to speak at such a timely and prestigious event that will provide excellent exposure for the Company. Further, we feel it speaks to the acceptance of our approach to this increasingly important and growing market sector".

ABOUT COMPASS BIOTECHNOLOGIES INC.

http://www.compassbio.net

Compass Biotechnologies is a publically-traded specialty biopharmaceutical company (COBI:OB) with headquarters in Edmonton, Alberta. The mission of Compass is to develop generic, biosimiliar and bio-better drug products that can bring revenue generation to the company in a near term fashion. A recent agreement with PanGen to supply protein active pharmaceutical ingredients to facilitate this mission was announced recently. Further Compass under a license from the National Institutes of Health (NIH) has opportunities to develop products from the platform technology available and or sub licensee these opportunities to other interested partners. Compass Biotech also owns a subsidiary company called C-Pharma Inc.

ABOUT C-PHARMA INC.

http://www.c-pharma.net

C-Pharma's technology encompasses the use of recombinant DNA technology to manufacture virus like particles (VLPs). These VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as Hepatitis C. The recombinant antigens presented in the context of a VLP carrier system are much more immunogenic than the antigen alone, and this carrier is so powerful that the subsequent vaccine may not require the use of immune adjuvants. C-Pharma is using the technology to develop a Hepatitis C vaccine to prevent hepatitis C viral infection of liver hepatocytes. The Company is also pursuing a revenue generation strategy by commercializing generic therapeutic drugs (ribavirin and interferon alpha) for use in the Hepatitis C market.
 
luckylindy  - posted
COBI's Top 4 Top Investor Highlights


#1. COBI has recently received proposal of a planned financing of Ten Million which is expected to tremendously jump start its operations!

#2. COBI is entering an industry with a growth prospect to more than Two Hundred Thirty Nine Billion by 2015.

#3. COBI has recently acquired an exclusive license from ARECOR LTD, from Cambridge UK!

#5. COBI is witnessing bullish technical indicators along with the “high growth” in the industry.
 
CAPTNEMOS  - posted
read the 10k before investing.no revenues and dont plan on any this year according to there Ceo.good luck if you bought in.Financially they are doomed.i bet r/m within 2yrs.

http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=89753&name=COMPAS S%20BIOTECHNOLOGIES%20INC.:%2010-K,%20Sub-Doc%201&link=http%3A//quotemedia.10kwi zard.com/filing.xml%3Frid%3D23%26ipage%3D7621933%26DSEQ%3D1%26SQDESC%3DSECTION_B ODY%26doc%3D1&cp=off&type=HTML
 
CAPTNEMOS  - posted
We do not have any immediate customers for any of our technologies. Future customers will consist of other biotechnology companies or pharmaceutical companies which we anticipate we will license our developed technologies to, in a partnership relationship for further commercial development.

Suppliers

In the previous fiscal year we were not reliant upon any one supplier.

As we move forward our company will not be reliant upon any suppliers for the research and development of our technologies.

Competition

The biotechnology and pharmaceutical industries are highly competitive. Numerous entities in the United States and elsewhere compete with our efforts to commercialize similar technologies. Our competitors include pharmaceutical, biomedical, biotechnology, academic and research institutions and governmental and other publicly and privately funded research agencies. We face, and expect to continue to face, competition from these entities to the extent that they develop products that have a function similar or identical to the function of our technologies.

Because many of our competitors have substantially greater capital resources and more experience in research and development, manufacturing and marketing than we do, we may not succeed in developing our proposed products and bringing them to market in a cost-effective and timely manner.

8

We are a development stage company engaged exclusively in research and development. We have not yet completed the development of our first product and have no revenue from operations. As a result, we may have difficulty competing with larger, established biomedical and pharmaceutical companies. These companies and organizations have much greater financial, technical, research, marketing, sales, distribution, service and other resources than us. Moreover, they may offer broader product lines, services and have greater name recognition than we do, and may offer discounts as a competitive tactic.

Government regulation

Our research and development activities and the manufacturing and marketing of our technology are subject to the laws and regulations of governmental authorities in the United States and any other countries in which our technology is ultimately marketed. In the United States, the Food and Drug Administration, or FDA, among other activities, regulates new product approvals to establish safety and efficacy of the types of products and technologies our company is currently developing. Governments in other countries have similar requirements for testing and marketing.

Regulation by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacture and marketing of our proposed technologies and in our ongoing research and development activities.

The products and technologies that we are currently researching and developing will require regulatory approval by governmental agencies prior to commercialization. Various federal statutes and regulations also govern or influence the testing, manufacturing, safety, labeling, storage, record keeping, and marketing of therapeutic products. The process of obtaining these approvals and the subsequent compliance with applicable statutes and regulations require the expenditure of substantial time and financial resources. Any failure by us or our collaborators, licensors or licensees to obtain, or any delay in obtaining regulatory approval, could have a material adverse effect on our business.

Item 1A. Risk Factors
GENERAL STATEMENT ABOUT RISKS

An investment in our common stock involves a number of very significant risks. You should carefully consider the following risks and uncertainties in addition to other information in this annual report in evaluating our company and our business before purchasing shares of our company's common stock. Our business, operating results and financial condition could be seriously harmed due to any of the following risks. You could lose all or part of your investment due to any of these risks.

RISKS RELATED TO OUR BUSINESS

We have had negative cash flows from operations since inception. We will require significant additional financing, the availability of which cannot be assured, and if our company is unable to obtain such financing, our business may fail.

To date, we have had negative cash flows from operations and have depended on sales of our equity securities and debt financing to meet our cash requirements. Our ability to develop and, if warranted, commercialize our technologies, will be dependent upon our ability to raise significant additional financing. If we are unable to obtain such financing, we will not be able to fully develop our business. Specifically, we will need to raise additional funds to:

support our planned growth and carry out our business plan;

continue scientific progress in our research and development programs;

9

address costs and timing of conducting clinical trials and seek regulatory approvals and patent prosecutions;

address competing technological and market developments; and

establish additional collaborative relationships.

We may not be able to obtain additional equity or debt financing on acceptable terms as required. Even if financing is available, it may not be available on terms that are favorable to us or in sufficient amounts to satisfy our requirements. If we require, but are unable to obtain, additional financing in the future, we may be unable to implement our business plan and our growth strategies, respond to changing business or economic conditions, withstand adverse operating results and compete effectively. More importantly, if we are unable to raise further financing when required, we may be forced to scale down our operations and our ability to generate revenues may be negatively affected.

We have a history of losses and nominal operating results, which raise substantial doubt about our ability to continue as a going concern.

Since inception through January 31, 2011, we have a net loss of $3,372,038. We can offer no assurance that we will operate profitably or that we will generate positive cash flow in the future. In addition, our operating results in the future may be subject to significant fluctuations due to many factors not within our control, such as the level of competition and general economic conditions.

Our company's operations will be subject to all the risks inherent in the establishment of a developing enterprise and the uncertainties arising from the absence of a significant operating history. No assurance can be given that we may be able to operate on a profitable basis.

Due to the nature of our business and the early stage of our development, our securities must be considered highly speculative. We have not realized a profit from our operations to date and there is little likelihood that we will realize any profits in the short or medium term. Any profitability in the future from our business will be dependent upon the successful commercialization or licensing of our core technology, which itself is subject to numerous risks.

We expect to continue to incur development costs and operating costs. Consequently, we expect to incur operating losses and negative cash flows until our technology gains market acceptance sufficient to generate a sustainable level of income from the commercialization or licensing of our technology.

Our inability to complete our product development activities successfully may severely limit our ability to operate and finance operations.

Commercialization of our core technology will require significant additional research and development as well as substantial clinical trials. We believe that the United States will be the principal market for our technology, as will any country in the world where the need for anti cancer therapeutics, initially for skin cancer and melanomas, exists. We may not be able to successfully complete development of our core technology, or successfully market our technology. We, and any of our potential collaborators, may encounter problems and delays relating to research and development, regulatory approval and intellectual property rights of our technology. Our research and development programs may not be successful. Our core technology may not prove to be safe and efficacious in clinical trials, and we may not obtain the intended regulatory approvals for our core technology. Whether or not any of these events occur, we may not have adequate resources to continue operations for the period required to resolve the issue delaying commercialization and we may not be able to raise capital to finance our continued operation during the period required for resolution of that issue.

10

We may lose our competitiveness if we are not able to protect our proprietary technology and intellectual property rights against infringement, and any related litigation may be time-consuming and costly.

Our success and ability to compete depends to a significant degree on our proprietary technology. If any of our competitors copy or otherwise gain access to our proprietary technology or develop similar technologies independently, we may not be able to compete as effectively. The measures we have implemented to protect our proprietary technology and other intellectual property rights are currently based upon a combination of patents and trade secrets. This, however, may not be adequate to prevent the unauthorized use of our proprietary technology and our other intellectual property rights. Further, the laws of foreign countries may provide inadequate protection of such intellectual property rights. We may need to bring legal claims to enforce or protect such intellectual property rights. Any litigation, whether successful or unsuccessful, may result in substantial costs and a diversion of our company's resources. In addition, notwithstanding our rights to our intellectual property, other persons may bring claims against us alleging that we have infringed on their intellectual property rights or claims that our intellectual property rights are not valid. Any claims against us, with or without merit, could be time consuming and costly to defend or litigate, divert our attention and resources, result in the loss of goodwill associated with our business or require us to make changes to our technology.

Our company may become subject to intellectual property litigation which may harm our business.

Our success depends in part on our ability to develop commercially viable products without infringing the proprietary rights of others. Although we have not been subject to any filed infringement claims, other patents could exist or could be filed which may prohibit or limit our ability to market our products or maintain a competitive position. In the event of an intellectual property dispute, we may be forced to litigate. Intellectual property litigation may divert management's attention from developing our technology and may force us to incur substantial costs regardless of whether we are successful. An adverse outcome could subject us to significant liabilities to third parties, and force us to curtail or cease the development and commercialization of our technology.

If our company commercializes or tests our technology, our company will be subject to potential product liability claims which may affect our earnings and financial condition.

We face an inherent business risk of exposure to product liability claims in the event that the use of our core technology during research and development efforts, including clinical trials, or after commercialization, results in adverse affects. As a result, we may incur significant product liability exposure, which may exceed any insurance coverage that we obtain in the future. Even if we elect to purchase such issuance in the future, we may not be able to maintain adequate levels of insurance at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims may increase our operating loss and affect our financial condition.

If we fail to effectively manage the growth of our company and the commercialization or licensing of our technology, our future business results could be harmed and our managerial and operational resources may be strained.

As we proceed with the development of our technology and the expansion of our marketing and commercialization efforts, we expect to experience significant growth in the scope and complexity of our business. We will need to add staff to manage operations, handle business development efforts and perform finance and accounting functions. We anticipate that we will be required to hire a broad range of additional personnel in order to successfully advance our operations. This growth is likely to place a strain on our management and operational resources. The failure to develop and implement effective systems, or to hire and retain sufficient personnel for the performance of all of the functions necessary to effectively service and manage our potential business, or the failure to manage growth effectively, could have a material adverse effect on our business and financial condition.

11

Failure to obtain and maintain required regulatory approvals will severely limit our ability to commercialize our technology.

We believe that it is important for the success of our business to obtain the approval of the Food and Drug Administration in the United States (FDA) before we commence commercialization of our technology in the United States, the principal market for our technology. We may also be required to obtain additional approvals from foreign regulatory authorities to apply for any sales activities we may carry out in those jurisdictions. If we cannot demonstrate the safety, reliability and efficacy of our technology, the FDA or other regulatory authorities could delay or withhold regulatory approval of our technology.

Even if we obtain regulatory approval of our technology, that approval may be subject to limitations on the indicated uses for which it may be marketed. Even after granting regulatory approval, the FDA and other regulatory agencies and governments in other countries will continue to review and inspect any future marketed products as well as any manufacturing facilities that we may establish in the future. Later discovery of previously unknown problems with a product or facility may result in restrictions on the product, including a withdrawal of the product from the market. Further, governmental regulatory agencies may establish additional regulations which could prevent or delay regulatory approval of our technology.

Even if we obtain regulatory approval to commercialize our products, lack of commercial acceptance may impair our business.

Our product development efforts are primarily directed toward obtaining regulatory approval for our protein product treatments. Our products may not be employed in all potential applications being investigated, and any reduction in applications may limit the market acceptance of our products and our potential revenues. As a result, even if our products are developed into marketable products and we obtain all required regulatory approvals, we cannot be certain that our products will be adopted at a level that would allow us to operate profitably.

If we do not keep pace with our competitors, technological advancements and market changes, our technology may become obsolete and our business may suffer.

The market for our technology is very competitive, is subject to rapid technological changes and varies for different individual products. We believe that there are potentially many competitive approaches being pursued that compete with our technology, including some by private companies for which information is difficult to obtain.

Many of our competitors have significantly greater resources and have developed products and processes that directly compete with our technology. Our competitors may develop, or may in the future develop, new technologies that directly compete with our technology or even render our technology obsolete. Our technology is designed to develop a topical treatment for skin cancer and melanoma. Even if we are able to demonstrate improved or equivalent results from our technology, researchers and practitioners may not use our technology and we may suffer a competitive disadvantage. Finally, to the extent that others develop new technologies that address the targeted application for our current technology, our business will suffer.

Our business is subject to comprehensive government regulation and any change in such regulation may have a material adverse effect on our company.

There is no assurance that the laws, regulations, policies or current administrative practices of any government body, organization or regulatory agency in the United States or any other jurisdiction, will not be changed, applied or interpreted in a manner which will fundamentally alter the ability of our company to carry on our business. The actions, policies or regulations, or changes thereto, of any government body or regulatory agency, or other special interest groups, may have a detrimental effect on our company. Any or all of these situations may have a negative impact on our operations.

12

RISKS RELATED TO OUR COMMON STOCK

A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our ability to continue operations.

A prolonged decline in the price of our common stock could result in a reduction in the liquidity of our common stock and a reduction in our ability to raise capital. Because a significant portion of our operations has been and will be financed through the sale of equity securities, a decline in the price of our common stock could be especially detrimental to our liquidity and our operations. Such reductions may force us to reallocate funds from other planned uses and may have a significant negative effect on our business plans and operations, including our ability to develop new products and continue our current operations. If our stock price declines, we can offer no assurance that we will be able to raise additional capital or generate funds from operations sufficient to meet our obligations. If we are unable to raise sufficient capital in the future, we may not be able to have the resources to continue our normal operations.

The market price for our common stock may also be affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations, even if minor, may have a material adverse effect on the market price of our common stock.

Trading of our stock may be restricted by the Securities Exchange Commission's penny stock regulations, which may limit a stockholder's ability to buy and sell our stock.

The Securities and Exchange Commission has adopted regulations which generally define "penny stock" to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and "accredited investors". The term "accredited investor" refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the Securities and Exchange Commission, which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our common stock.

The Financial Industry Regulatory Authority, or FINRA, has adopted sales practice requirements which may also limit a stockholder's ability to buy and sell our stock.

In addition to the "penny stock" rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low priced securities will not be suitable for at least some customers.

13

FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

Our common stock is illiquid and the price of our common stock may be negatively impacted by factors which are unrelated to our operations.

Our common stock currently trades on a limited basis on the OTC Bulletin Board. Trading of our stock through the OTC Bulletin Board is frequently thin and highly volatile. There is no assurance that a sufficient market will develop in the stock, in which case it could be difficult for shareholders to sell their stock. The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of our competitors, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our competitors or us. In addition, the stock market is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.

Other Risks

Trends, Risks and Uncertainties

We have sought to identify what we believe to be the most significant risks to our business, but we cannot predict whether, or to what extent, any of such risks may be realized nor can we guarantee that we have identified all possible risks that might arise. Investors should carefully consider all of such risk factors before making an investment decision with respect to our common stock.

Item 1B. Unresolved Staff Comments
As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Properties
Executive Offices

Our principal business offices are located at Unit 131 Advanced Technology Center, 9650 - 20th Avenue NW, Edmonton, Alberta, Canada. We lease approximately 450 sq. feet at a cost of $542.16 per month for our use of these premises. We believe that our current lease arrangements provide adequate pace for our foreseeable future needs.

Item 3. Legal Proceedings
We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

Item 4. [Removed and Reserved]
14

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common shares are quoted on the Over-the-Counter Bulletin Board and the OTC Link under the symbol “COBI”. The following quotations obtained from Stockwatch reflect the high and low bids for our common stock based on inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.

The high and low bid prices of our common stock for the periods indicated below are as follows:

OTC Bulletin Board(1)
Quarter Ended High Low
January 31, 2011 $0.35 $0.30
October 31, 2010 $0.46 $0.065
July 31, 2010 $0.51 $0.11
April 30, 2010 $0.60 $0.219
January 31, 2010 $0.10 $0.04
October 31, 2009 $0.05 $0.05
July 31, 2009 $1.15 $0.2
April 30, 2009 n/a n/a
January 31, 2009 $0.02 $0.009
(1) Over-the-counter market quotations reflect inter-dealer prices without retail mark-up, mark-down or commission, and may not represent actual transactions.

Our shares of common stock are issued in registered form. The registrar and transfer agent for our shares of common stock is Pacific Stock Transfer Company, Suite 240, 500 E. Warm Springs Road, Las Vegas, Nevada 89119 (Telephone: 702.361.3303; Facsimile: 702. 433.1979) .

On May 17, 2011, the shareholders' list showed 91 registered shareholders and 19,842,621 common shares outstanding.

Dividend Policy

We have not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined from time to time by our board of directors.

Equity Compensation Plan Information

On March 31, 2007 our board of directors approved our 2007 stock option plan. Under the 2007 stock option plan, options may be granted only to our directors, officers, employees and consultants as determined by our board of directors.

15

The following table summarizes certain information regarding our equity compensation plan as at January 31, 2011 (post split):

Equity Compensation Plan Information


Plan category

Number of securities to
be issued upon exercise of
outstanding options,
warrants and rights

Weighted-average
exercise price of
outstanding options,
warrants and rights Number of securities
remaining available for
future issuance under
equity compensation plans
(excluding securities
reflected in column (a))
Equity compensation plans
approved by security
holders
Nil

Nil

Nil
Equity compensation plans
not approved by security holders 4,000
500,000
$30.40 $0.18 2,496,000
Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

Other than as disclosed below, we did not sell any equity securities which were not registered under the Securities Act during the year ended January 31, 2011 that were not otherwise disclosed on our quarterly reports on Form 10-Q or our current reports on Form 8-K filed during the year ended January 31, 2011.

Purchase of Equity Securities by the Issuer and Affiliated Purchasers

We did not purchase any of our shares of common stock or other securities during our fourth quarter of our fiscal year ended January 31, 2011.

Item 6. Selected Financial Data
As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our audited financial statements and the related notes for the years ended January 31, 2011 and January 31, 2010 that appear elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this registration statement, particularly in the section entitled "Risk Factors" beginning on page 9 of this annual report.

Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

Purchase of Significant Equipment

We do not intend to purchase any significant equipment over the next twelve months.

16

Personnel Plan

If our financing plans are successful we do expect that the number of employees and consultants retained by the Company to increase. This would be a reflection of the increase in activity of developing our products and moving them through the various studies and clinical trials required. We do and will continue to outsource contract employment as needed. However as we may be limited in our financing efforts we are taking a conservative approach in providing the next period of operations and activity levels.

Results of Operations

For the Year Ending January 31, 2011 and 2010

Year Ended
January 31
2011 2010
(Restated)
Revenue $ Nil $ Nil
Operating Expenses $ 1,418,218 $ 406,239
Net Income (Loss) $ (1,489,171 ) $ (341,109 )
Expenses

Our operating expenses for our years ended January 31, 2011 and 2010 are outlined in the table below:

Year Ended
January 31
2011 2010
(Restated)
Amortization $ 78,074 $ 621
General and administrative $ 1,128,517 $ 229,834
Management fees $ 105,050 $ 87,479
Research and development $ 105,050 $ 87,479
Travel $ 1,527 $ 826
Operating expenses for year ended January 31, 2011, increased by approximately 249% as compared to the comparative period in 2010 primarily as a result of increase in amortization of licenses by $77,228, increase in management fees by $17,570, increase in research and development fees by $17,570, increase in consulting fees by $830,763 and increase in other general and administrative fees by $67,920.

Revenue

We have not earned any revenues since our inception and we do not anticipate earning revenues in the upcoming

Equity Compensation

On March 31, 2007 our board of directors approved our 2007 stock option plan. Under the 2007 stock option plan, options may be granted only to our directors, officers, employees and consultants as determined by our board of directors. Pursuant to the Plan, we reserved for issuance 3,000,000 pre-split shares of our common stock (75,000 post split shares of our common stock).

17

Liquidity and Financial Condition

Working Capital

At At
January 31, January 31,
2011 2010 Increase/
(Restated) (Decrease)
Current Assets $ 310,185 $ 59,045 $ 251,140
Current Liabilities $ 699,182 $ 220,782 $ 448,400
Working Capital (deficit) $ (388,997 ) $ (65,737 ) $ (323,260 )

Cash Flows
Year Ended Year Ended
January 31, January 31,
2011 2010
Net Cash Used in Operating Activities $ 339,950 $ 188,733
Net Cash Used in Investing Activities $ 4,351 $ 98,288
Net Cash Provided by Financing Activities $ 386,601 $ 278,358
Increase in Cash During the Period $ 35,208 $ (21,035 )
In the next twelve months we anticipate spending $360,000 on management fees, $250,000 on general and administrative expenses and $1,180,000 on research and development. Our cash on hand at January 31, 2011 was $40,126. We plan to raise additional capital required to meet immediate short-term needs and to meet the balance of our estimated funding requirements for the twelve months, primarily through the private placement of our securities.

We are not aware of any known trends, demands, commitments, events or uncertainties that will result in or that are reasonably likely to result in our liquidity increasing or decreasing in any material way.

Future Financings

We will require additional financing in order to enable us to proceed with our plan of operations, as discussed above, including approximately $1,790,000 over the next 12 months to pay for our ongoing operating expenses. These cash requirements are in excess of our current cash and working capital resources. Accordingly, we will require additional financing in order to continue operations and to repay our liabilities. There is no assurance that any party will advance additional funds to us in order to enable us to sustain our plan of operations or to repay our liabilities.

We anticipate continuing to rely on equity sales of our common stock in order to continue to fund our business operations. Issuances of additional shares will result in dilution to our existing stockholders. There is no assurance that we will achieve any additional sales of our equity securities or arrange for debt or other financing to fund our planned business activities.

Other than as described below, we presently do not have any arrangements for additional financing and no potential lines of credit or sources of financing are currently available for the purpose of proceeding with our plan of operations.

Cash Requirements

Estimated Funding Required During the Twelve Month Period Ending January 31, 2012

Operating Expenses
Management and Consulting $ 360,000
Research and Development 1,180,000
General and Administrative 250,000
Total Operating Expenses $ 1,790,000
18

Due to the uncertainty of our ability to meet our current operating and capital expenses, in their report on the annual financial statements for the year ended January 31, 2011, our independent auditors included an explanatory paragraph regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

As a result, there will also be substantial doubt about our ability to continue as a going concern as the continuation of our business will be dependent upon obtaining further financing and achieving a profitable level of operations. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of the stockholders who will be receiving our shares in the spin off. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments.

There are no assurances that we will be able to obtain further funds required for our continued operations. We intend to pursue various financing alternatives to meet our immediate and long-term financial requirements, which we anticipate will consist of further private placements of our equity securities or shareholder loans. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we will not be able to meet our obligations as they become due and we will be forced to further scale down or perhaps even cease operations.

As noted, we are pursuing various financing alternatives to meet our immediate and long-term financial requirements, which we anticipate will consist of further private placements of equity securities, advances from related parties or shareholder loans. We plan to rely on shareholder loans and private placements to meet our short term cash requirements. We have not entered into any definitive agreements with any shareholders or related parties for the provision of loans or advances. There can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, or generate significant material revenues from operations, we will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease our operations.

Contractual Obligations

As a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

Going Concern

We anticipate that additional funding will be required in the form of equity financing from the sale of our common stock. At this time, we cannot provide investors with any assurance that we will be able to raise sufficient funding from the sale of our common stock or through a loan from our directors to meet our obligations over the next twelve months. We do not have any arrangements in place for any future debt or equity financing.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

Basis of Presentation

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in US dollars. Our company’s fiscal year end is January 31.

19

Principles of Consolidation

These financial statements include the accounts of our company and its wholly-owned subsidiary, C-Pharma Inc. (formerly Cyplasin OncoScience Inc.). All significant intercompany transactions and balances have been eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Our company’s actual results could differ from management’s estimates and assumptions. Significant areas requiring the use of management estimates relate to the determination of impairment of intangibles and long lived assets, fair value of stock-based transactions, expected tax rates for future income tax recoveries and determining the fair values of financial statements.

Foreign Currency Translation

The Company’s functional currency is the Canadian dollar. The financial statements of the Company are translated to United States dollar equivalents. Monetary assets and liabilities denominated in foreign currencies are translated into United States dollar equivalents at rates of exchange in effect at the balance sheet date. Average rates for the year are used to translate revenues and expenses.

The cumulative translation adjustment is reported as a separate component of accumulated other comprehensive income, whereas gains and losses arising from foreign currency translations are included in results of operations.

Equipment

Equipment consists of computer hardware, furniture and equipment and is recorded at cost. Computer hardware and furniture and equipment are depreciated on a straight-line basis over their estimated lives of three years and five years, respectively.

Intangible Assets

Goodwill and intangible assets with indefinite lives are not amortized but are annually tested for impairment. The determination of any impairment includes a comparison of the estimated future operating cash flows anticipated during the remaining life for the net carrying value of the asset as well as a comparison of the fair value to the book value of the Company or the reporting unit to which the goodwill can be attributed. Intangible assets with finite life are amortized over their useful life on a straight line basis. Management has determined that the Company’s license to patents to be used in the development of vaccination for the prevention and treatment of hepatitis C to have a useful life of 10 years.

Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable at the end of each reporting period. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent of manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, management measures fair value based on quoted market prices or based on discounted estimates of future cash flows.

Research and Development

Research and product development costs are expensed as incurred.

20

Other Comprehensive Income

Our company reports and displays comprehensive income and its components in the financial statements. During the years ended January 31, 2011 and 2010, the only component of comprehensive income was foreign currency translation adjustments.

Income Taxes

Our company uses the assets and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Our company accounts for uncertainty in income taxes by prescribing the recognition threshold that a tax position is required to meet before any part of the benefit of that position may be recognized in the financial statements.

Basic and Diluted Loss per Share

Basic loss per share is computed using the weighted average number of common shares outstanding during the year. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. For the years presented, diluted loss per share is equal to basic loss per share as the effect of the computations are anti-dilutive.

Financial Instruments and Risk Management

The carrying value of our company’s financial instruments, consisting of cash, receivables and accounts payable and accrued liabilities approximates their fair value due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that our company is not exposed to significant interest, currency or credit risks arising from these financial instruments.

Our company’s operations are in Canada and virtually all of its assets and liabilities are giving rise to significant exposure to market risks from changes in foreign currency rates. The financial risk is the risk to our company’s operations that arise from fluctuations in foreign exchange rates and the degree of volatility of these rates. Currently, our company does not use derivative instruments to reduce its exposure to foreign currency risk.

Stock-Based Compensation

Our company records the compensation cost related to share-based payments, such as stock options and employee stock purchase plans, in the financial statements based on the grant-date fair value of the award.

Comparative figures

Certain of the comparative figures have been reclassified to conform to the current year’s presentation.

Recent Accounting Pronouncements

In January 2010, the Financial Accounting Standard Board (“FASB”) issued Accounting Standards Update (“ASU “) 2010-06, Improving Disclosures about Fair Value Measurements, which is included in the ASC Topic 820 (Fair Value Measurements and Disclosures). ASU 2010-06 requires new disclosures on the amount and reason for transfers in and out of Level 1 and 2 fair value measurements. ASU 2010-06 also requires disclosures of activities, including purchases, sales, issuances, and a settlement within Level 3 fair value measurements and clarifies existing disclosure requirements on levels of disaggregation and disclosures about inputs and valuation techniques. ASU 2010-06 is effective for interim and annual reporting periods beginning after December 15, 2009 except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. The implementation of the adoption of ASU 2010-06 did not have a material impact on the Company’s consolidated financial statements.

21

In February 2010, the FASB issued ASU 2010-09, "Subsequent Events (Topic 855) Amendments to Certain Recognition and Disclosure Requirements". The amendment eliminates the requirement for SEC filers to disclose the date through which subsequent events have been evaluated. This standard had no impact on the Company's consolidated financial statements.

There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe any of these accounting pronouncements has had or will have a material impact on the Company's financial position or operating results.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk
As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 8. Financial Statements and Supplementary Data
22


COMPASS BIOTECHNOLOGIES INC
(FORMERLY CYPLASIN BIOMEDICAL, LTD.)
(A Development Stage Company)
January 31, 2011

Index

Report of Independent Registered Public Accounting Firm F–1
Consolidated Balance Sheets F–2
Consolidated Statements of Operations F–3
Consolidated Statement of Stockholders’ Equity F–4
Consolidated Statements of Cash Flows F–5
Notes to Consolidated Financial Statements F–6 – F-15


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors of Compass Biotechnologies Inc. (formerly Cyplasin Biomedical, Ltd):

We have audited the accompanying consolidated balance sheets of Compass Biotechnologies Inc. (formerly Cyplasin Biomedical, Ltd) (a development stage company) as of January 31, 2011 and 2010 and the related consolidated statements of operations, stockholders’ equity and cash flows for the years then ended and for the period from February 15, 2007 (date of reporting as a development stage company) to January 31, 2011. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, these consolidated financial statements present fairly, in all material respects, the financial position of Compass Biotechnologies Inc. as of January 31, 2011 and 2010 and the results of its operations and its cash flows for the years then ended and for the period from February 15, 2007 (date of reporting as a development stage company) to January 31, 2011 in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has not generated revenues since inception, has incurred losses in developing its business, and further losses are anticipated. The Company requires additional funds to meet its obligations and the costs of its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in this regard are described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company has restated its consolidated financial statements for the year ended January 31, 2010 to reflect correction of an error (Note 14). Accordingly, our present opinion on the 2010 financial statements, as presented herein, is not different from our previous report dated May 14, 2010, whereby we expressed an opinion that the 2010 financial statements fairly presented the financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America.

/s/ DMCL

DALE MATHESON CARR-HILTON LABONTE LLP
CHARTERED ACCOUNTANTS
Vancouver, Canada
May 17, 2011


F - 1


COMPASS BIOTECHNOLOGIES INC. (FORMERLY CYPLASIN BIOMEDICAL, LTD.)
(A Development Stage Company)
Consolidated Balance Sheets

January 31, January 31,
2011 2010
$ $
(Restated -
Note 14)
ASSETS

Current Assets
Cash 40,126 4,918
Receivable 45,071 32,019
Prepaids (Note 7) 224,988 22,108
Total Current Assets 310,185 59,045
Accounts receivable (Note 4) – 69,335
Equipment, net (Note 3) 730 1,576
Licenses, net (Note 5) 695,050 740,427
Total Assets 1,005,965 870,383

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued liabilities (Notes 5, 6, 9 and 10) 685,682 210,782
Promissory note (Note 6) 13,500 10,000
Total Liabilities 699,182 220,782

Contingency (Note 1)
Commitments (Note 4, 5 and 10)
Subsequent events (Note 15)
Stockholders’ equity
Common stock (Note 7)
Authorized: 100,000,000 shares of common stock, par value $0.001
and 100,000,000 shares of preferred stock, par value $0.001




Issued and outstanding: 15,729,053 common shares (January 31, 2010 – 4,104,200) 15,729 4,104
Additional paid-in capital 3,422,506 1,638,211
Accumulated other comprehensive income 21,664 28,756
Obligation to issue shares (Note 5 and 10) 113,875 654,475
Subscriptions receivable (Note 7) (10,200 ) –
Subscriptions received (Note 7) 115,247 206,922
Deficit (54,275 ) (54,275 )
Deficit accumulated during the development stage (3,317,763 ) (1,828,592 )
Total Stockholders’ Equity 306,783 649,601
Total Liabilities and Stockholders’ Equity 1,005,965 870,383
The accompanying notes are an integral part of these consolidated financial statements.

F - 2


COMPASS BIOTECHNOLOGIES INC. (FORMERLY CYPLASIN BIOMEDICAL, LTD.)
(A Development Stage Company)
Consolidated Statements of Operations

Accumulated From
February 15, 2007
(Date of reporting as
a development stage
company) Year Year
to Ended Ended
January 31, January 31, January 31,
2011 2011 2010
$ $ $
(Restated -
Note 14)

Operating Expenses

Amortization 79,407 78,074 621
General and administrative 1,855,048 1,128,517 229,834
Management fees (Note 9) 365,711 105,050 87,479
Research and development (Note 9) 995,435 105,050 87,479
Travel 16,339 1,527 826

Loss Before Other Items (3,311,940 ) (1,418,218 ) (406,239 )

Other Items
Gain on sale of patent (Note 4) 70,025 – 70,025
Loss on settlement of debt (Note 9) (4,894 ) – (4,894 )
Write-off of patent (Note 4) (1 ) – (1 )
Write-off of accounts receivable (Note 4) (70,953 ) (70,953 ) –
Net Loss (3,317,763 ) (1,489,171 ) (341,109 )

Loss Per Share – Basic and Diluted (0.14 ) (0.16 )

Weighted Average Shares Outstanding – Basic and Diluted 10,618,572 2,125,849
The accompanying notes are an integral part of these consolidated financial statements.

F - 3


COMPASS BIOTECHNOLOGIES INC. (FORMERLY CYPLASIN BIOMEDICAL, LTD.)
(A Development Stage Company)
Consolidated Statement of Stockholders’ Equity

Deficit
Additional Accumulated accumulated
Common Paid-in Other Obligation to during the
Common Stock Capital Comprehensive issue shares Subscriptions Subscriptions development
Stock Amount Income (Loss) receivable received Deficit stage Total
Number $ $ $ $ $ $ $ $ $
Balance, January 31, 2007 and February 15, 2007 (date of reporting as a development stage company) 1,770,100 1,770 54,831 (168 ) – – – 8,394 – 64,827
Common stock issued 525,000 525 (524 ) – – – – – – 1
Common stock cancelled (1,333,000 ) (1,333 ) 1,333 – – – – – – –
Private placements 42,500 28 1,099,972 – – – – – – 11,000,000
Stock-based compensation – – 115,131 – – – – – – 115,131
Foreign currency translation – – – 70,339 – – – – – 70,339
Net loss – – – – – – – (62,669 ) (856,380 ) (919,049 )
Balance, January 31, 2008 989,600 990 1,270,743 70,171 – – – (54,275 ) (856,380 ) 431,249
Stock-based compensation – – 193,368 – – – – – – 193,368
Foreign currency translation – – – (29,043 ) – – – – – (29,043 )
Net loss – – – – – – – – (631,103 ) (631,103 )
Balance, January 31, 2009 989,600 990 1,464,111 41,128 – – – (54,275 ) (1,487,483 ) (35,529 )
Private placements 1,725,000 1,725 84,975 – – – – – – 86,700
Shares for debt 669,600 669 32,811 – – – – – – 33,480
Shares for consulting 400,000 400 39,600 – – – – – – 40,000
Finder’s shares 320,000 320 31,680 – – – – – – 32,000
Finder’s fees – – (69,962 ) – – – – – – (69,962 )
Stock-based compensation – – 54,996 – – – – – – 54,996
Obligation to issue shares – – – 654,475 – – – – 654,475
Foreign currency translation – – – (12,372 ) – – – – – (12,372 )
Subscriptions received – – – – – – 206,922 – – 206,922
– –
Net loss(Restated – Note 14) – – – – – – (341,109 ) (341,109 )
Balance, January 31, 2010 4,104,200 4,104 1,638,211 28,756 654,475 – 206,922 (54,275 ) (1,828,592 ) 649,601
Private placements 5,194,853 5,195 520,934 – – (10,200 ) (187,266 ) – – 328,663
Shares for consulting 2,750,000 2,750 877,750 – – – – – – 880,500
Shares for license 3,180,000 3,180 537,420 – 540,600
Obligation to issue shares – – – – (540,600 ) – – – – (540,600 )
Finder’s shares 500,000 500 49,500 – – – – – – 50,000
Share issuance costs – – (214,909 ) – – – – – – (214,909 )
Stock based compensation – – 13,600 – – – – – – 13,600
Foreign currency translation – – – (7,092 ) – – – – – (7,092 )
Subscriptions received – – – – – – 95,591 – – 95,591
– –
Net loss – – – – – – (1,489,171 ) (1,489,171 )
Balance, January 31, 2011 15,729,053 15,729 3,422,506 21,664 113,875 (10,200 ) 115,247 (54,275 ) (3,317,763 ) 306,783
The accompanying notes are an integral part of these consolidated financial statements

F - 4


COMPASS BIOTECHNOLOGIES INC. (FORMERLY CYPLASIN BIOMEDICAL, LTD.)
(A Development Stage Company)
Consolidated Statements of Cash Flows

Accumulated
From
February 15, 2007
(Date of reporting
as a development
stage company) Year Year
To Ended Ended
January 31, January 31, January 31,
2011 2011 2010
$ $ $
(Restated -
Note 14)

Cash Flows From Operating Activities

Net loss (3,372,038 ) (1,489,171 ) (341,109 )

Adjustments to reconcile net income (loss) to net cash
provided by (used in) operating activities:




Amortization 79,407 78,074 621
Gain on sale of patent (70,025 ) – (70,025 )
Foreign exchange on gain on sale of patent 790 – 790
Loss on settlement of debt 4,894 – 4,894
Accrued interest 2,322 2,322 –
Shares for consulting services 732,308 692,308 40,000
Obligation to issue shares for consulting services 28,875 – 28,875
Stock-based compensation 377,095 13,600 54,996
Write-off of patent 1 – 1
Write-off of accounts receivable 69,335 69,335 –

Changes in operating assets and liabilities:

Receivable (45,071 ) (13,052 ) (13,859 )
Prepaids (58,904 ) (36,796 ) (16,687 )
Accounts payable and accrued liabilities 552,564 343,430 122,770

Net Cash Used in Operating Activities (1,698,447 ) (339,950 ) (188,733 )
Cash Flows From Investing Activities

Acquisition of equipment (2,909 ) – (997 )
Acquisition of patent (100 ) – –
Acquisition of licenses for patents (101,642 ) (4,351 ) (97,291 )

Net Cash Used in Investing Activities (104,651 ) (4,351 ) (98,288 )

Cash Flows From Financing Activities

Proceeds from loan payable 13,500 3,500 10,000
Issuance of common stock 1,505,547 287,510 61,436
Subscriptions received 302,513 95,591 206,922

Net Cash Provided By Financing Activities 1,821,560 386,601 278,358

Effect of Exchange Rate Changes 21,664 (7,092 ) (12,372 )

Change in Cash 40,126 35,208 (21,035 )

Cash– Beginning – 4,918 25,953

Cash– Ending 40,126 40,126 4,918
Supplemental Cash Flow Information – Note 12

The accompanying notes are an integral part of these consolidated financial statements.

F - 5


Compass Biotechnologies Inc. (formerly Cyplasin BioMedical, Ltd.)
(A Development Stage Company)
Notes to Consolidated Financial Statements
January 31, 2011

1.
Nature of Operations and Going Concern


Compass Biotechnologies Inc. (formerly Cyplasin Biomedical, Ltd.) (the “Company”) was incorporated in the state of Nevada on November 25, 2004 and is a development stage company. Effective March 29, 2011, the Company entered into an agreement and plan of merger with its wholly-owned subsidiary whereby the subsidiary merged with and into the Company and effected a name change to Compass Biotechnologies Inc. The Company’s shares are quoted on the OTC-BB.


Pursuant to Asset Purchase Agreements (Note 4), the Company had acquired intellectual property comprised of patents used in the development of cancer treatment technology. During the year ended January 31, 2010, the Company wrote- off and sold these patents due to a change in focus of the Company’s business and acquired licenses for patents pertaining to the technology utilized in the prevention and treatment of hepatitis C (Note 5).


The accompanying consolidated financial statements have been prepared on the basis of a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next fiscal year. At January 31, 2011, the Company had not yet achieved profitable operations and has accumulated losses of $3,372,038 (2010 - $1,882,867) since its inception and has a working capital deficiency of $388,997 (2010 - $161,737). The continuing operations of the Company are dependent upon its ability to raise adequate financing to develop its technology for production.


Realization values may be substantially different from the carrying values shown on these financial statements. These consolidated financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. Since internally generated cash flow will not fund development and commercialization of the Company’s technology, the Company will require significant additional financial resources and will be dependent on future financings to fund its ongoing operations as well as other working capital requirements. The Company’s future capital requirements will depend on many factors including the rate and extent of progress in its development and commercialization program. There can be no assurance that the Company will be successful in its efforts to raise additional financing or if financing is available, that it will be on terms that are acceptable to the Company.


Management is addressing going concern remediation through raising additional sources of capital for operations and planned commercialization. Management’s plans are intended to increase the Company’s financial stability and to improve the efficiency of continuing operations. The Company intends to generate funds from future production of hepatitis C therapy products and raising funds from investors via equity. It is expected that the Company may incur further losses in the development of its business, all of which casts reasonable doubt about the Company’s ability to continue as a going concern.
 
wolyton  - posted
EDMONTON, May 31, 2011 /PRNewswire via COMTEX/ -- Compass Biotechnologies (COBI:OB) is pleased to announce that Dr. Joseph Sinkule President and COO of Compass Biotech has been invited to speak at the fourth annual World Generic Medicines Congress Americas 2011 to be held this fall from November 12 - November 15 at the Westin Grand, Washington D.C.

The Congress is the largest of its kind within the Generics Industry and for the first time this year is expanding to include the World Biosimiliars Summit to help focus on the key challenges facing the commercialization of the soon to be multiple billion dollar biosimiliar US and global markets.

The meeting unites a speaker platform of the highest seniority with all stakeholders in the industry and allows participants to position their products and services in front of decision makers from major Pharma manufacturers and large biotech companies. Dr. Sinkule who will speak on "Strategies and Opportunities for Smaller and Niche Generic Companies"

Dr Sinkule commented "It is indeed an honour and a privilege to be invited to speak at such a timely and prestigious event that will provide excellent exposure for the Company. Further, we feel it speaks to the acceptance of our approach to this increasingly important and growing market sector".
 
wolyton  - posted
gonna rebound quickly i believe.
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share